HC Wainwright & Co. Reiterates Buy on SAB Biotherapeutics, Maintains $4 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Edward White reiterates a Buy rating on SAB Biotherapeutics (NASDAQ:SABS) and maintains a $4 price target.
June 21, 2023 | 3:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Edward White reiterates a Buy rating on SAB Biotherapeutics and maintains a $4 price target.
The reiterated Buy rating and maintained $4 price target by HC Wainwright & Co. analyst Edward White indicates a positive outlook for SAB Biotherapeutics. This news is likely to have a positive short-term impact on the stock price as it reaffirms the analyst's confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100